<DOC>
	<DOCNO>NCT00597818</DOCNO>
	<brief_summary>The primary purpose study determine efficacy safety three dose level cobiprostone compare placebo OA/RA patient treat NSAID .</brief_summary>
	<brief_title>Cobiprostone Prevention NSAID-induced Gastroduodenal Injury</brief_title>
	<detailed_description />
	<mesh_term>Wounds Injuries</mesh_term>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Patient 40 less 70 year age . Patient confirm osteoarthritis ( OA ) and/or rheumatoid arthritis ( RA ) could benefit NSAID therapy . No current gastrointestinal H. pylorus infection . Known allergy hypersensitivity NSAIDs , contraindicate condition ( ) NSAID therapy . Patient undergone gastrointestinal abdominal surgical procedure within 90 day prior Screening Visit , bowel resection time . Medical history include prior active GI complication and/or disorder , include limited Barrett 's esophagus , erosive esophagitis , esophageal stricture ring , gastric obstruction , irritable bowel syndrome ( IBS ) , inflammatory bowel disease ( IBD ) . Active symptomatic peptic ulcer disease GI bleeding . Patient receive cobiprostone ( SPI8811 ; RU8811 ) AMITIZA ( lubiprostone , SPI0211 , RU0211 ) time prior participation study .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2010</verification_date>
</DOC>